{"id":"NCT04379713","sponsor":"Pfizer","briefTitle":"20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants","officialTitle":"A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-05-21","primaryCompletion":"2022-08-31","completion":"2022-08-31","firstPosted":"2020-05-07","resultsPosted":"2023-06-13","lastUpdate":"2023-06-13"},"enrollment":1511,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Disease"],"interventions":[{"type":"BIOLOGICAL","name":"20-valent pneumococcal conjugate vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"13-valent pneumococcal conjugate vaccine","otherNames":[]}],"arms":[{"label":"20-valent pneumococcal conjugate vaccine","type":"EXPERIMENTAL"},{"label":"13-valent pneumococcal conjugate vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.","primaryOutcome":{"measure":"Percentage of Participants With Local Reactions Within 7 Days After Dose 1","timeFrame":"Within 7 Days after Dose 1","effectByArm":[{"arm":"20vPnC","deltaMin":18,"sd":15.7},{"arm":"13vPnC","deltaMin":16.5,"sd":13.3}],"pValues":[]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":97,"countries":["United States","Argentina","Canada","Chile","Czechia","Finland","Germany","Greece","Hungary","Puerto Rico","Spain"]},"refs":{"pmids":[],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B7471013"]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":1000},"commonTop":["Irritability (IRRITABILITY)","Hypersomnia (INCREASED SLEEP)","Injection site pain (PAIN)","Decreased appetite (DECREASED APPETITE)","Injection site erythema (REDNESS)"]}}